### Core Concept

Fulvestrant is a selective estrogen receptor downregulator (SERD) used in the treatment of hormone receptor-positive metastatic breast cancer. It works by degrading the estrogen receptor (ER), thereby inhibiting estrogen-mediated gene expression.

### Why the Correct Answer is Right

Fulvestrant binds to the estrogen receptor, inducing conformational changes that promote its degradation through the ubiquitin-proteasome pathway. This downregulation of estrogen receptors leads to a decrease in estrogen-mediated transcriptional activity, ultimately inhibiting tumor growth. The mechanism of action involves the disruption of the estrogen receptor's interaction with coactivators and the recruitment of corepressors.

### Why Each Wrong Option is Incorrect

**Option A:** Incorrect because Fulvestrant does indeed have a role in downregulating estrogen receptors.

**Option B:** Incorrect because the correct term is selective estrogen receptor downregulator (SERD), not selective estrogen receptor modulator (SERM).

**Option C:** Incorrect because while Fulvestrant is administered intramuscularly, its mechanism of action is not related to its route of administration.

**Option D:** Incorrect because Fulvestrant's primary mechanism of action is through the degradation of estrogen receptors, not by direct inhibition of estrogen synthesis.

### Clinical Pearl / High-Yield Fact

Fulvestrant's unique mechanism of action sets it apart from other endocrine therapies, such as aromatase inhibitors, which inhibit estrogen synthesis. This distinction highlights the importance of understanding the specific mechanisms of action for various endocrine therapies in managing hormone receptor-positive breast cancer.

### Correct Answer: B. Fulvestrant is a selective estrogen receptor downregulator (SERD) and not a selective estrogen receptor modulator (SERM).